-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yimaitong edited and sorted, please do not reprint
without authorization.
1.
2022 Update: Nutrition and lifestyle recommendations for patients with
On July 11, Austria updated the 2014 version of the proposal to publish the "2022 update: nutrition and lifestyle recommendations for patients with gout and hyperuricemia", which formulated a total of 10 practical recommendations
.
This recommendation does not distinguish between gout and hyperuricemia because the primary goal for both groups of patients is to lower
.
Summary of nutrition and lifestyle recommendations:
Recommended reading: The latest nutrition and lifestyle recommendations for gout and hyperuricemia: These four types of foods should be "avoided" | Guide consensus
2.
Canadian College of Rheumatology: Guidelines for the management of antirheumatic drugs for
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis, in which patients develop gradual destruction of joint cartilage and bone, eventually leading to joint deformity and loss of
function.
In recent years, with the prolongation of the course of the disease, the incidence of disability and functional limitations has continued to increase
.
Rational use of disease-modifying antirheumatic drugs is a key step
in the management of RA.
On July 15, the Canadian College of Rheumatology issued guidelines for the use of bDMARDs and tsDMARDs in the treatment of RA
.
Recommended reading: When to stop biologics and targeted drugs? The latest foreign rheumatoid arthritis guidelines recommend | Guide consensus
3.
American College of Rheumatology (ACR): Guidelines for vaccination of patients with rheumatism and musculoskeletal disorders
Infection prevention is essential in patient management in rheumatology patients due to the increased burden of infection due to immune disorders, comorbidities, and immunosuppressive therapy, and vaccines can prevent infection
by inducing and/or enhancing protective immunity.
In July 2022, the American College of Rheumatology (ACR) updated its vaccination guidelines for patients with rheumatology and musculoskeletal disorders (RMDs) to provide evidence-based recommendations
for vaccination for children and adults with RMDs.
Recommended reading: Latest ACR guidelines: What vaccines can people with rheumatism receive? | Guide consensus
4.
Preoperative management of rheumatology and
The use of drugs such as immunosuppressants, biologics and nonsteroidal anti-inflammatory drugs (NSAIDs) has increased
significantly over the past 20 years.
Considering the benefits and risks of drug withdrawal, perioperative management may be challenging
in clinical practice.
On August 1, the International Organization Society for Perioperative Assessment and Quality Improvement (SPAQI) released the Preoperative Management of Rheumatology and AIDS Drugs: SPAQI Consensus Statement, which provides practical guidance
for the preoperative management of immunosuppressants, biologics, and NSAIDs.
Recommended reading: What drugs should be stopped before surgery in rheumatoid patients? | Guide consensus
5.
Consensus statement on blocking interleukin-6 receptors and interleukin-6 under inflammatory conditions: recent progress
Targeting interleukin(IL)-6 has become the mainstay of therapeutic strategies for immune-mediated inflammatory diseases, interfering with specific receptors
of the IL-6 pathway by anti-IL-6Rα antibodies or direct inhibition of IL-6 cytokines.
On August 11, the "Consensus Statement on Blocking Interleukin-6 Receptors and Interleukin-6 under Inflammatory Conditions: Recent Progress" was released, based on the latest evidence and expert opinions, it gave guidance and recommendations on the clinical application of IL-6 inhibitors, covering nine diseases
including rheumatoid arthritis, polyarticular course and systemic
Pretreatment screening, safety, and contraindications
for IL-6 inhibitors are also discussed.
Recommended reading: Expert consensus on the clinical application of IL-6 inhibitors: nine indications and dosage | Guide consensus
6.
Expert consensus on the diagnosis and treatment of latent infection with Mycobacterium
Patients with rheumatic disease are at increased risk of immunocompromise, latent Mycobacterium tuberculosis (LTBI) infection, and significantly increased risk of developing active tuberculosis, and clinicians need to be tested
for LTBI in these eligible populations.
To this end, domestic experts in the field of tuberculosis and rheumatic diseases jointly wrote and released the "Expert Consensus on the Diagnosis and Treatment of Mycobacterium tuberculosis Latent Infection in Patients with Rheumatic Diseases" (referred to as the consensus).
Based on the epidemiology, evidence-based medical evidence and clinical research data of rheumatic diseases combined with LTBI in China, 10 recommendations are put forward for clinical reference
.
Screening and treatment process:
Recommended reading: How to screen rheumatic patients for TB infection? List of the 10 Recommendations of the Latest China Consensus | Guide consensus
7.
ACR: 2022 Glucocorticoid Osteoporosis (GIOP) Prevention and Treatment Recommendations
Glucocorticoid osteoporosis (GIOP) is one of the most common adverse reactions of hormones, and severe cases can cause
patients.
In September, the American College of Rheumatology (ACR) developed updated GIOP guidelines (expected to be officially released in early 2023) to build on the 2017 guidelines
.
Recommended reading: ACR Guide to Early Fetch! Summary of recommendations for the prevention and treatment of glucocorticoid osteoporosis (GIOP) in 2022 | Guide consensus
